The recently published ‘The quality of medical products for cardiovascular diseases: a gap in global cardiac care’ paper, shows that one fifth of medicines reported as sampled in the literature were substandard or falsified. The research was carried out by experts from the MORU Tropical Health Network together with IDDO scientists.
Given the very limited available data, the obtained findings – out of 4,703 medical products for cardiovascular diseases samples, 17.5 per cent were falsified or substandard – cannot be extrapolated.
Nevertheless, due to the critical role of these products in cardiovascular diseases management, poor quality cardiovascular medicines and medical devices will inevitably have adverse health impacts for patients, both short and long term, and can also be life-threatening.
